Skip to main navigation

Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

11.29.23

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

11.27.23

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

11.14.23

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

11.13.23

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

11.9.23

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

11.3.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

11.2.23

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

10.19.23

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

10.16.23

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

10.3.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2023 Terns Pharmaceuticals, Inc. Privacy Policy